TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that ...
TransCode Therapeutics, in partnership with Quantum Leap Healthcare Collaborative, has submitted an IND application amendment ...
TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study, designed to generate critical data to support evaluation of the safety and tolerability of ...
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, ...
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results